OpenOnco
UA EN

Onco Wiki / Actionability

NRAS codon 12 mutation in mCRC — extended RAS WT criterion fails; anti-EGFR contraindicat...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDBMA-NRAS-G12-CRC
TypeActionability
Statusreviewed 2026-04-27 | pending_clinical_signoff | actionability review required
DiseasesDIS-CRC
SourcesSRC-CIVIC SRC-NCCN-COLON-2025

Actionability Facts

BiomarkerBIO-RAS-MUTATION
VariantNRAS G12
DiseaseDIS-CRC
ESCAT tierIB
Contraindicated monotherapycetuximab / panitumumab
Evidence summaryNRAS codon 12 mutation in mCRC — extended RAS WT criterion fails; anti-EGFR contraindicated.

Notes

ESCAT IB.

Used By

No reverse references found in the YAML corpus.